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ABSTRACT
Objectives: This paper describes the methods used in
the International Cancer Benchmarking Partnership
Module 4 Survey (ICBPM4) which examines time
intervals and routes to cancer diagnosis in 10
jurisdictions. We present the study design with
defining and measuring time intervals, identifying
patients with cancer, questionnaire development, data
management and analyses.
Design and setting: Recruitment of participants to
the ICBPM4 survey is based on cancer registries in
each jurisdiction. Questionnaires draw on previous
instruments and have been through a process of
cognitive testing and piloting in three jurisdictions
followed by standardised translation and adaptation.
Data analysis focuses on comparing differences in
time intervals and routes to diagnosis in the
jurisdictions.
Participants: Our target is 200 patients with
symptomatic breast, lung, colorectal and ovarian
cancer in each jurisdiction. Patients are approached
directly or via their primary care physician (PCP).
Patients’ PCPs and cancer treatment specialists (CTSs)
are surveyed, and ‘data rules’ are applied to combine
and reconcile conflicting information. Where
CTS information is unavailable, audit information
is sought from treatment records and databases.
Main outcomes: Reliability testing of the patient
questionnaire showed that agreement was complete
(κ=1) in four items and substantial (κ=0.8, 95% CI
0.333 to 1) in one item. The identification of eligible
patients is sufficient to meet the targets for breast,
lung and colorectal cancer. Initial patient and PCP
survey response rates from the UK and Sweden are
comparable with similar published surveys. Data
collection was completed in early 2016 for all cancer
types.
Conclusion: An international questionnaire-based
survey of patients with cancer, PCPs and CTSs has
been developed and launched in 10 jurisdictions.
ICBPM4 will help to further understand international
differences in cancer survival by comparing time
intervals and routes to cancer diagnosis.
BACKGROUND
The International Cancer Benchmarking
Partnership (ICBP) is a major international
collaboration which is exploring differences
in cancer survival between Australia, Canada,
Denmark, Norway, Sweden and the UK.1 It has
Strengths and limitations of this study
▪ There are no previous examples of applying stan-
dardised survey methods in a broad range of jur-
isdictions to examine components of diagnostic
intervals in cancer.
▪ This study could provide unique insights into
why cancer survival differences exist in different
regions of the world.
▪ International Cancer Benchmarking Partnership
Module 4 Survey is a questionnaire-based
survey, and results are subject to limitations and
caveats—particularly those arising from non-
response bias and external validity.
▪ Response to a questionnaire on diagnostic jour-
neys in patients with cancer may be influenced
by factors which differ across jurisdictions, com-
pounding existing non-response bias.
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already demonstrated significant differences in 1-year
and 5-year relative survival for breast, lung, colorectal
and ovarian cancers among participating jurisdictions.2
Recent data confirm that significant disparities in
cancer survival persist across a range of tumour types
in Europe.3 The ICBP further seeks to systematically
explore population and healthcare-related factors in rela-
tion to these variations in cancer survival. Survival differ-
ences between populations are most probably due to a
range of factors including lifestyle, levels of comorbidity,
availability of screening programmes, primary care system,
and availability and quality of diagnostic and treatment
services.2 4–7 Module 4 of the ICBP (ICBPM4) aims to:
▸ Compare time intervals (patient, primary care,
diagnostic and treatment and total intervals—see
figure 1) between jurisdictions.
▸ Identify the proportion of patients entering the cancer
pathway through different routes (eg, symptom-based
diagnosis, screening, via accident and emergency
(A&E)) and analyse the association with time intervals
within jurisdictions.
▸ Analyse the association between time intervals (out-
lined in the methods section) and cancer outcomes
in participating jurisdictions and identify where
actions to reduce delays could be focused.
The central research question of ICBPM4 is: ‘can var-
iations in cancer survival between jurisdictions partici-
pating in the International Cancer Benchmarking
Partnership be explained by differences in routes to
diagnosis?’ Routes to diagnosis have an important influ-
ence on cancer outcomes and patient experience. For
common cancers, such as colorectal cancer, available
evidence suggests that longer patient intervals (the
time from first noticing symptoms to seeking help) are
associated with poorer survival,8 and that longer diag-
nostic intervals (from first presentation until diagnosis)
increase mortality.9–12 There is a growing body of evi-
dence examining the relationship between various
components of the diagnostic journey and long-term
cancer outcomes; emergency presentation is typically
associated with worse patient outcomes, and this nega-
tive effect persists after adjustment for stage.13 Further,
while their number of prediagnosis consultations has
not been quantified, qualitative evidence suggests that
patients who present as emergencies typically have pro-
longed, circuitous pathways, in which consultations are
not necessarily a conduit to diagnosis.14 There is some
observational evidence that prolonged primary care
time intervals can adversely affect outcomes, and
similar associations are found with longer treatment
intervals,15 although evidence across a range of cancers
is mixed.12 In terms of patient experience, it is known
that patients prioritise rapid investigation for cancer,16
and ‘time to diagnosis’ affects patients’ confidence in
the healthcare system.17 Hence, investigating differ-
ences in routes to cancer diagnosis between different
countries can help in assessing the possible impact on
cancer survival.
Accordingly, there is a great deal of interest in short-
ening diagnostic intervals through better access to in-
vestigations, and decision aids in primary care,18 19 as
there are some indications that variation in access, and
readiness to use, diagnostic investigations might influ-
ence cancer outcomes;6 20 the gatekeeping function in
primary care may also influence diagnostic intervals.21
Longer diagnostic intervals may lead to cancers which are
more advanced at the time of diagnosis; there is some evi-
dence, for example, of later stage diagnoses in the UK
compared to other countries, notably for lung and colo-
rectal cancers.22 23 Further, treatment intervals have been
shown to be associated with stage progression.24 25
ICBP Module 1 showed that cancer survival is higher
in Sweden, Canada and Australia, intermediate in
Norway and lower in Denmark and the UK.2 Further
analysis in Module 1 suggests that differences in treat-
ment and access to optimal treatment may be impacting
on survival outcomes, alongside evident ‘delays’ in diag-
nosis.4 26 ICBP Module 2 demonstrated that awareness
and beliefs about cancer are unlikely to explain inter-
national survival differences but may form part of a more
complex picture.5 ICBP Module 3 compared primary
care systems and found differences in primary care phys-
ician (PCP) readiness to investigate between countries
that could be related to cancer outcomes.6 Given the
international differences in survival and the scientific
basis for the importance of routes to cancer diagnosis
and treatment, a detailed examination of international
differences in diagnostic pathways is important.
The purpose of this paper is to present the study
design (highlighting key issues in defining and measur-
ing milestones and time intervals), and to report on pro-
cesses of identifying patients with cancer, questionnaire
development, data management and analyses.
Management of ICBP
The ICBP is overseen by a Programme Board with repre-
sentatives from all participating jurisdictions. The Board
meets regularly to review progress and findings from
each of the modules. Dedicated module chairs, overseeing
each module, report to the Programme Board. ICBPM4 is
led by a central academic team with module co-chairs and
senior researchers based at University College London
(UCL), UK, the University of Edinburgh, UK and Aarhus
University, Denmark. Cancer Research UK provides pro-
gramme management support to the central team.27 The
ICBPM4 central academic team and the overall pro-
gramme management are funded jointly by participating
jurisdictions. Each of the ICBPM4 jurisdictions has an
individual lead and management team to conduct their
own local survey. Regular meetings take place between the
jurisdiction leads and the central academic team.
ICBPM4 study design
The study is an international, multicentre, cross-
sectional, population-based survey of newly diagnosed
patients with cancer. Ten jurisdictions (Australia (Victoria),
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Canada (Manitoba, Ontario), Denmark, Norway, Sweden
and the UK (England, Northern Ireland, Scotland and
Wales)) are participating. These jurisdictions were selected
as they are considered to be reasonably similar regarding
access and expenditure on healthcare and level of cancer
treatment but show variation in cancer survival. They all
have comprehensive cancer registration facilitating inter-
national studies.1
In common with other ICBP modules,2 four cancers
are included—breast, ovarian, colorectal and lung
cancer. There is variation among these cancers in terms
of their symptom characteristics, availability of screening,
treatments and effects of other factors like age and
comorbidity. For a given period in each jurisdiction,
newly diagnosed patients with cancer were identified
and a questionnaire was sent to the patient, the PCP and
the diagnosing/treating hospital. The questionnaire
focused particularly on specific milestones, time intervals
and the routes to diagnosis. The study was initiated in
2009 and the data collection launched in 2013. Data col-
lection finished in early 2016.
Routes to diagnosis
An understanding of differences in routes to diagnosis
between jurisdictions is important to understand differ-
ences in time intervals and where, if feasible, to focus an
intervention. Cancers may be diagnosed through routes
other than symptomatic presentation to primary care,
such as screening or direct presentation to a specialist or
hospital emergency department. The survey sought to
capture this variety of diagnostic routes.
Nevertheless, it is difficult to capture complex patient
journeys in surveys; the questionnaire drew on previous
‘routes to diagnosis’ research13 but we refined previous
definitions of time points and intervals, using guidance
from the Aarhus Statement.28 Further, we specified
routes to be explored as: (1) symptoms/a bodily change
prompting a doctor’s visit; (2) symptoms/a bodily
change prompting a visit to accident and emergency
(A&E); (3) combinations of (1) and (2); (4) incidental
diagnosis in the course of investigation or treatment for
another problem; (5) participation in a population-
based cancer screening programme; (6) other route.
Using these predefined routes, it was possible to stand-
ardise data between jurisdictions—it also made our clas-
sifications consistent with those used in ICBP Module 3,
enabling the combination of data with these modules in
future analyses.6
Measuring time points and intervals
A central aim of ICBPM4 is to measure and compare
time intervals (patient, primary care, diagnostic and
treatment intervals) in participating jurisdictions. To
build on the best existing knowledge and conceptualisa-
tion of time intervals, we used the Aarhus Statement28
(see figure 1) and focused on four key time points,
defined as shown in table 1. We sought to define, as pre-
cisely as possible, the different time intervals, as meas-
urement of time points can all present methodological
challenges—it is also necessary to decide which source
of data (patient, PCP, CTS) is preferred for each of the
time points, in order to generate data rules when there
are multiple sources of information:
▸ Date of first symptom—cancer symptoms can be mul-
tiple, vague and non-specific, making it difficult to
precisely identify this date (collected, in ICBPM4,
from patient and PCP. Preferred reporting source:
patient).
▸ Date of first presentation to primary care—similarly,
it is often difficult to establish which ‘presentation’ in
primary care represents the first time a patient seeks
help about cancer-related symptoms (collected from
patient and PCP. Preferred reporting source: PCP).
▸ Date of referral—there can be confusion over the
date on which the PCP engages specialist diagnos-
tic and treatment services for the patient’s ongoing
management; in this study, we defined date of first
referral as the date where the PCP transferred the
Figure 1 Key time points and
diagnostic intervals in the route
from first symptom until start of
treatment.28 36 PCP, primary care
physician.
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responsibility for further diagnosis and treatment to
specialist services (collected from PCP).
▸ Date of diagnosis—a range of definitions exist,
including dates of (1) tissue diagnosis and (2) receiv-
ing results of investigations. Therefore, respondents
were asked to report date of diagnosis and, addition-
ally, what they based their understanding of date of
diagnosis on (collected from patient, PCP and CTS.
Preferred reporting source: CTS >PCP >patient)
Examples of questions we used to gather information
about these time points (from the patient with breast
cancer questionnaire) are shown in table 2. Further
complexity arises from the nature of diagnostic pathways;
patients do not typically follow a linear pattern from the
onset of symptoms to presentation in primary care to
diagnosis and treatment; sometimes there will be cross
referrals; other patients will be returned to primary care
only to be referred to a different service. Hence, while
this research seeks to measure discrete intervals, there is
recognition that time points and intervals can be diffi-
cult to identify and measure accurately.
Health-related visits and investigations
In addition to time points and intervals, ICBPM4 seeks
information on the volume of visits to healthcare provi-
ders and diagnostic facilities amongst patient respon-
dents. Hence, we included, in the patient survey,
questions on types (and number) of health-related visits
in the lead up to patients’ cancer diagnosis.
Questionnaire development and pilot testing
For data collection, we chose a questionnaire-based
survey (complemented by registry data where appropri-
ate and possible). While interviews might provide an
opportunity to better capture patient journey complex-
ity,29 this would have been difficult to standardise across
10 jurisdictions, given translation and local adaptation
issues. This method also allowed us to include significant
numbers of patients with cancer and enhance statistical
precision.
To be able to triangulate and supplement reports of
time points and intervals, we chose a strategy where we,
for each individual patient, survey the patient with
cancer, the patient’s PCP and the CTS. Reports of diag-
nostic pathways can vary between patients and their
healthcare providers;30–32 our approach takes account of
this variation. Accordingly, the data collection comprises
three surveys per cancer:
▸ Patients with cancer: own experiences of symptoms
are vital in determining the onset of symptoms, how
long it took to seek help and consultations/investiga-
tions along the path to diagnosis.
▸ Patients’ PCPs: are an important source of data on
the cancer diagnostic pathway31 as most patients
present to primary care with symptoms and primary
care records are a good source of information on, for
example, comorbidity.
▸ Patients’ CTSs: are a particularly important source of
diagnostic and treatment information.
Questionnaire item generation
We developed a core questionnaire based on the prede-
fined list of required variables. This core questionnaire
was then developed further for each of the four cancers
in order to adjust for cancer-specific issues. While guid-
ance on measuring time points and intervals in the
cancer patient pathway is available,28 until now there is
no widely accepted, validated instrument for use in such
surveys. We generated a series of questions from existing
instruments in Denmark and the UK,32 33 and comple-
mented this with an item generation exercise involving
senior members of the ICBP team. Wording of the ques-
tions reflected a balance between providing enough
detail to address the complexity of patient journeys,
avoiding an overly burdensome instrument and getting a
standardised description. To allow for characterisation
and comparison of patients with cancer between coun-
tries and different groups, we included items on poten-
tial confounders, including comorbidity, smoking, age,
gender and educational level.
Table 1 Time point definitions based on the ‘Aarhus Statement’28
Date of first symptom The time point when first bodily changes and/or symptoms are noticed. Should encompass several
key components: the date when the first bodily change was noticed, the date when the first symptom
was noticed, the date when the person perceives a reason to discuss the symptom with a healthcare
professional and the date when the first ‘alarm’ or ‘high-risk’ symptom was noticed.
Date of first
presentation
The time point at which, given the presenting signs, symptoms, history and other risk factors, it would
be at least possible for the clinician seeing the patient to have started investigation or referral for
possible important pathology, including cancer.
Date of referral The time point at which there is a transfer of responsibility from one healthcare provider to another
(typically, in ‘gatekeeper’ healthcare systems, from a primary care provider to a doctor/service
specialising in cancer diagnosis and management) for further clinical diagnostic and management
activity, relating to the patient’s suspected cancer. Patients may be referred more than once or
between specialists.
Date of diagnosis Studies should be explicit about how the date is measured, and should consult the well-developed
hierarchical rationales available in the public domain in choosing their definition of date of diagnosis.
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Based on this work, three core questionnaires for each
cancer were developed in English (a total of 12 ques-
tionnaires). Jurisdictions were able to add a small
number of locally relevant questions to the core ques-
tionnaire—these are not included in the core analyses.
Cognitive testing of draft instrument
Based on established principles of questionnaire devel-
opment,34 the questionnaires underwent a process of
cognitive testing, exploring the understanding of items
and use of the responses. We also sought feedback on
any ambiguous question wording, layout and order.
Cognitive testing was undertaken in England and
Scotland from February to May 2012. Patients were pro-
vided with the draft questions in advance, and then
asked to provide feedback via focus groups, telephone,
face-to-face interviews and email. A total of 14 patients
took part in this exercise; in England, patients were
recruited opportunistically while attending a
gynaecological clinic, while in Scotland they were
recruited through a general practice in Edinburgh.
Five PCPs and eight CTSs in the UK also provided
feedback on the PCP and CTS versions of the question-
naire. Beside participants’ overall assessment of the
questionnaire, participants were asked for each item:
▸ Is the meaning of this question, and why we are
asking it, clear?
▸ Did you have any trouble answering this question?
▸ Do you have any suggestions on how this question
could be improved?
As a result of cognitive testing, wording of several items
was modified, with the aim of achieving greater clarity
and ease of completion. The questionnaires were revised
and reformatted to produce a version for piloting.
Pilot-testing
This was undertaken in three jurisdictions—England,
Northern Ireland and Victoria. The pilot was designed
to (1) test identification and recruitment procedures
Table 2 Areas of enquiry, number of items and extracts of questions used to elicit time points (example from breast cancer
questionnaires)
Patient
▸ Background (1)
▸ Route to diagnosis
(eg, via PCP, A&E) (1)
▸ Description of symptoms and date first
noticed (2)
▸ Time taken to consult doctor (1)
▸ Time to get an appointment and date
seen (2)
▸ Number of health professional visits (1)
▸ Time taken to get CTS appointment (2)
▸ Date of diagnosis (1)
▸ Description of treatments received (1)
▸ Details of CTS (1)
▸ General health and comorbidity (2)
▸ Sociodemographics (3)
▸ Smoking status (3)
PCP
▸ Duration of symptoms prior to
presentation (1)
▸ Route to diagnosis (1)
▸ Investigations ordered and dates (1)
▸ Date of referral to CTS, and details of
referral (3)
▸ Date of diagnosis (1)
▸ Comorbidity information (1)
CTS
▸ Date of first attendance for
specialist services (1)
▸ Route of referral (1)
▸ Where patient seen (1)
▸ Date of diagnosis (1)
▸ Date cancer treatment started (1)
▸ Tumour information (2)
Date of first symptom (patient questionnaire)
Please write down your best estimate of the date you noticed … any symptom(s) you may have had before contacting a
doctor or taking part in screening
Date of first presentation to primary care (patient questionnaire)
What was the date you first saw your doctor about your health concern(s) or symptom(s)?
Date of first presentation to primary care (PCP questionnaire)
Through what route did the patient first present? (if your patient first presented to primary care, either in-hours or out-of hours).
Can you please provide your best approximation of the date of his primary care visit?
Date of referral (PCP questionnaire)
At what date did you first refer the patient to hospital or another specialist, thereby transferring the responsibility for ongoing
investigation/treatment to other medical services?
Date of diagnosis (patient questionnaire)
What was the date you were told you had cancer?
Date of diagnosis (PCP and CTS questionnaires)
Please indicate date of diagnosis: This can be decided in different ways; please tick and complete as many of the following
dates as possible: Date of histological confirmation; date of results of investigation confirming cancer;date patient was told;
date of biopsy; date patient was first admitted to hospital because of themalignancy;date of MDT confirmation of diagnosis;
other (please specify)
A&E, accident and emergency; CTS, cancer treatment specialists; MDT, multidisciplinary team; PCP, primary care physician..
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(see figure 2), and (2) seek further feedback on the
questionnaire and other study materials.
The pilot examined the key trial processes illustrated
in figure 2 including vital status checks (to ensure all
identified patients were alive before contacting these
patients’ individual PCP) and of PCP and patient aware-
ness of the cancer diagnosis. It also examined the
process of PCP forwarding of patient questionnaires (an
ethical requirement in England, Scotland, Wales and
Norway) and questionnaire completion rates.
The majority of pilot patients were in England where
patients were recruited from three cancer registries (as
they existed at the time—Trent Cancer Registry, the
Eastern Cancer Registration and Information Centre
and the West Midlands Cancer Intelligence Unit became
part of a single English registry during the course of our
study). Two hundred consecutive patients (50 per
cancer) were identified, of whom 144 (72%) were
female. After application of eligibility criteria and PCP
identification, 120 were sent to PCPs for forwarding to
patients.
PCPs forwarded 72 of the 120 questionnaires (59.7%)
to patients. The most common reported reasons for not
forwarding were ‘patient deceased’ or ‘change of
address’. Forty-three completed questionnaires were
received (36%); of these, 39 (90.7%) provided consent
Figure 2 Patient identification and data collection process for pilot in England (also documented in main study). PCP, primary
care physician.
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to have their PCPs and CTSs contacted. The response
rate for PCP and CTS surveys was 87% and 58%,
respectively.
Findings from all three regions of the pilot were
broadly similar, and highlighted the need to improve
recruitment and response rates through a range of
strategies:
▸ Improvement in questionnaire follow-up procedures.
▸ Change to patient recruitment period from 2–
6 months postdiagnosis to 3–6 months after diagnosis
to minimise numbers of patients still undergoing
active treatment and provide additional time for
patient’s cancer registrations to be validated.
▸ Reduction of complexity and burden of the
questionnaires—through improved formatting,
clearer response categories, more logical progression
through the questionnaires and removal of lengthy
items (such as those on comorbidity).
Reliability testing
Reliability is an important issue when measuring dates
and information exposed to recall bias. To improve reli-
ability, we used items that had been tested previously.
Further, 12 patients agreed to complete a second ques-
tionnaire after 2 weeks for a test–retest. Questions with
minimum 10 patients’ responses were included in the
analysis. The agreement for categorical variables was
assessed by κ coefficients. The CIs for κ were bias-
corrected using bootstrapping. The agreement for date
of diagnosis was assessed by a description of the vari-
ation in the differences between the dates. Among the
five categorical variables considered, the agreement was
substantial (κ=0.8, 95% CI 0.333 to 1) for one and
perfect (κ=1, 95% CI NA) in four (owing to the com-
plete agreement, the CI could not be calculated using
bootstrapping; the statistical precision might still, due to
the ambiguous assumptions, be difficult to establish).
For date of diagnosis, 54.5% of the responders reported
the same date, while for 18.2% and 27.3% the difference
was 1–8 days and more than 8 days, respectively.
Translation and cultural adaptation of the questionnaires
In Wales, while the questionnaire itself was not trans-
lated, the study summary and covering letter were trans-
lated into Welsh. Translated versions were required for
Sweden, Denmark and Norway. To make the process effi-
cient, the Scandinavian languages were serially trans-
lated. Once a Danish translated and culturally adapted
version of the questionnaire was produced, it was trans-
lated and culturally adapted for use in Sweden and
Norway. The Scandinavian translation was undertaken as
follows:
▸ Questionnaires were translated from English into
Danish by external translators with Danish as their
mother tongue.
▸ Translations were double checked for wording by
another independent highly English linguistic skilled
source with Danish as first language.
▸ The two versions were synthesised and problems dis-
cussed and resolved as follows:
– All questions with no discrepancies between transla-
tions—accepted.
– Questions with minor discrepancies in translations
—wording changed according to second linguistic
source by project group.
– Questions with other than minor discrepancies—
changed by consensus by international project
group and linguistic worker.
The final version was then translated from Danish into
Swedish and Norwegian with no back-translation. If
there were any questions and problems with the
Scandinavian translations, they were discussed and solved
at telephone meetings.
Field-testing and cultural adaptation in English-
speaking jurisdictions outside the UK was undertaken to
ensure that cultural, social and other contextual issues
were solved. In particular, differences in terminology
exist for some health-related words and phrases between
the countries. Further, differences in the structure of
health services between jurisdictions meant that terms such
as ‘referral’ or ‘primary care’ needed cultural adaptation.
At the completion of translation and local adaptation
processes, a final check was made by the central ICBP
team and jurisdiction leads to ensure consistency in
meaning and interpretation of the questionnaires across
jurisdictions. A summary of questionnaire items is shown
in table 2. The three questionnaires for each of the four
cancers are supplied (see online supplementary files S1–
S3). Researchers should get in touch with the ICBP pro-
gramme management team at icbp@cancer.org.uk prior
to referencing or using the ICBPM4 questionnaires.
Patient identification and recruitment
In each jurisdiction, the aim is to collect information
from 200 symptomatic patients and their associated PCPs
and CTSs for each of the four cancers. Since data from
patients whose cancers were screen-detected do not con-
tribute information about all relevant time points and
intervals, efforts are being made to recruit 200 patients
whose cancers were detected via a symptomatic route,
for each cancer in each jurisdiction. Expected recruit-
ment rates are lowest for ovarian cancer, and in Sweden
ovarian cancer is not included. Eligible participants are
consecutive, newly diagnosed patients with cancer diag-
nosed 3–6 months prior to identification through the
cancer registry. Inclusion and exclusion criteria are
shown in box 1.
All participating jurisdictions have comprehensive and
valid cancer registries, based on internationally accepted
criteria.35 Hence, we are able to undertake registry-based
recruitment of patients; while registries differ in their
capacity to identify patients in a timely manner,36 they
are the least likely of all patient identification methods
to produce sampling bias.37 There are minor differences
in recruitment approaches between jurisdictions, for
example, Northern Ireland verifies patient eligibility
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through checking by research nurses (see also online
supplementary file S4). There are minor differences in
the characteristics of cancer registries of participating
jurisdictions, but all are population-based registers with
strict monitoring of data quality.
There is some variation in methods of approaching
patients, PCPs and CTSs between jurisdictions (see online
supplementary file S4). These differences arise from
ethical constraints and variations in organisational proce-
dures. In some jurisdictions (such as England), patients
needed to be approached by their PCP rather than a
direct approach through cancer registries or directly from
the local research team. Jurisdictions also differ in the ways
they identify patient’s PCPs and CTSs, and in the ways they
are following up non-responders to the questionnaires.
Registries and clinical databases are used in jurisdic-
tions where questionnaire-based data collection from
primary and secondary care was not feasible. This is the
case, for example, in Denmark and Northern Ireland
data for the hospital component of the pathway.
A summary of identification and recruitment processes for
all jurisdictions is shown in online supplementary file S4.
Registry data
From each jurisdiction, available relevant registry data
are also collected. These data concern date of diagno-
sis, Tumour, Node, Metastases (TNM), Fédération
Internationale de Gynécologie et d’Obstétrique (FIGO)
and Dukes stage, possible date of death or vital status
12 months after date of diagnosis and screen detected
cancer. These data are collected for two purposes: to
describe all identified patients with cancer and describe
non-participation, and also to do additional analyses on
association with survival and mortality.
Sample size
Sample size considerations are based on the analysis of
longer time intervals (more than the 75th centile) across 10
jurisdictions. A reference point is chosen as the jurisdiction,
where most patients are expected to have the longest time
interval (defined as the largest 75th centile). The propor-
tion with the ‘short’ interval from the reference jurisdiction
will be compared with the proportions with ‘short’ intervals
from the rest of the jurisdictions—that is, nine comparisons
will be performed. Our aim is to be able to demonstrate a
minimum higher proportion of patients with such ‘short’
intervals of 85% (ie, an expected minimal important differ-
ence of 10%). The sample size calculation is based on
sample size determination for comparing proportions by χ2
test in contingency tables.38 We have adjusted the method
to accommodate our intention to undertake only nine com-
parisons. With a power of 90%, the method reveals a
requirement for an overall sample of size 2000—that is, 200
patients are required in each of 10 jurisdictions.
Data handling
ICBPM4 data collection is coordinated through the
team at UCL, UK, for seven of the jurisdictions. The
questionnaire data are entered locally by each of the 10
participating jurisdictions. Seven use a bespoke online
data management system (using the Microsoft SQL
Server), built by the team at UCL and tested during the
English pilot. The system incorporates relevant valid-
ation rules for entry of demographic and questionnaire
details. The data entered are then transferred without
personal identifiers to the central data repository at
UCL. Data entry in Victoria (Australia), Sweden and
Denmark is via a locally developed database delivered
directly to the analysis team in Denmark.
All jurisdictions have established mechanisms to
ensure data completeness and quality.
Data are forwarded to the team at University of
Aarhus, Denmark, for analysis. Consistent rules for inter-
preting data are applied to resolve any issues associated
with ‘incorrect’ responses and missing data. These
checks are applied consistently to data across all jurisdic-
tions and inconsistencies are discussed with the lead in
each jurisdiction. For specific variables on education,
ethnicity, comorbidity and smoking, specific standard
rules are applied to make the final categorisation of
these variables comparable across countries.
Analysis plan
The primary outcomes of the study are time intervals
and routes to diagnosis. A comparison of key diagnostic
Box 1 Inclusion and exclusion criteria for the four cancer
types in International Cancer Benchmarking Partnership
Module 4
Inclusion criteria:
1. Patients aged 40 years or more.
2. Diagnosis of primary (behaviour code 3 on the third revision of
the International Classification of Diseases for Oncology;
ICD-O-3) cancers with the following ICD10 codes
A. Breast: (C50.0—C50.9)
B. Ovary including the fallopian tube and adnexa (C56 (ICD-O-3
C56.9); C57.0—C57.9)
C. Lung and bronchus: (C34.0—C34.9)
D. Colorectal: colon (ICD-10 C18.0—C18.9), rectosigmoid junc-
tion (C19; ICD-O-3 C19.9) and rectum (C20; ICD-O-3 C20.9)
3. All patients with a qualifying index cancer were included, irre-
spective of whether it was their first, second or higher-order
cancer
4. Completion of patient questionnaire within 6 months of cancer
diagnosis
Exclusion criteria:
1. Patients where the tumour was benign (behaviour code 0), of
uncertain or borderline malignancy (behaviour code 1), in situ
(behaviour code 2) or metastatic to the index organ from else-
where (behaviour code 6).
2. Patients who had previously had a separate cancer of the same
organ (eg, consecutive breast cancers)
3. Patients who had cancers of the anus and anal canal (ICD-10
C21) and trachea (C33)
4. Male patients with breast cancer (C50)
5. Patients who have synchronous primary cancers
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intervals forms the core of our analyses. Since the time
intervals will be highly right-skewed, they will be mea-
sured with median, interquartiles and 90-centiles. For
time intervals, the adjustment will be performed by
quantile regression as this method allows for a compari-
son across the whole distribution of length of the inter-
val. Since the length of the interval in days is a
continuous measure which has been rounded, we will
use the ‘qcount’-routine proposed by Miranda.39 One
thousand jittered samples will be applied to calculate
the parameters of the model.
Where relevant, diagnostic routes will be stratified into
‘screening’ and ‘non-screening’. Adjustment will be
carried out with generalised linear models for the bino-
mial family to quantify the prevalence ratio for screening
route among jurisdictions. Prevalence ratio (PR) is
chosen as an outcome measure over OR, as PR can be
more readily understood and communicated—and OR
may overemphasise the likelihood when the prevalence
of the outcome measure is above 20%.40
Further, we will compare the number of health-related
visits and investigations, which is the secondary outcome
of the study. Numbers of health-related visits and investi-
gations are considered as counts and will be compared
across jurisdictions by using negative binomial regres-
sion. We plan to use negative binomial distribution to
ensure that potential non-equality of conditional mean
and conditional variance in the data is dealt with
appropriately.41
Univariable and multivariable models will be used.
The multivariable analyses will control for patient-related
factors such as sex, age, comorbidity, education and
whether a patient had cancer-specific symptoms.
Data quality analyses will be performed to identify
missing, incomplete, ‘out of range’ and inconsistent
data. This will include testing for negative (or very
large) time intervals and multiple responses (ie, cases
where there are two dates given in the same survey). We
have developed rules (see below) for handling conflict-
ing responses (eg, a respondent indicating that he/she
is both a smoker and non-smoker).
We are using three different sources of data on patient
journeys. Therefore, a comprehensive set of data rules
has been developed based on previous analyses in the UK
and Denmark. For some questions, we will have responses
from the patient and both their PCP and CTS. Hence,
for each question, there is a ‘hierarchy’ of responses and
we have decided a priori which source (patient, PCP or
CTS questionnaire) should take priority. For example, we
will preferentially use patient data for dates of first symp-
toms, and hospital data for diagnostic information, while
for ‘date of first presentation’ we are giving preference to
PCP responses. We also prioritise a specific date higher
than a less specific or a categorised time interval. The
exact data rules for each cancer site will be published in
the subsequent ICBPM4 papers.
We will report on validity and reliability between our
three data sources. This triangulation analysis will focus
on comparing items such as dates, intervals and routes
to diagnosis. The agreement for categorical variables will
be assessed by κ coefficients. The agreement for con-
tinuous variables will be measured by Lin’s concordance
correlation coefficient.42 If necessary, we will perform
transformation to account for the skewed data.
Validation by measuring against a gold standard will be
performed in those jurisdictions where data from a
registry are available.
Statistical analyses will be carried out using STATAV.14
software.
Ethical and other approvals
A list of the ethical, privacy and data approvals that we
received is shown in online supplementary file S5. All
jurisdictions have strict governance and privacy regula-
tions for use of cancer registry data—in particular to
ensure that confidentiality of patient information is not
compromised.
Preliminary response rates
Online supplementary file S6 provides a summary of
progress with patient and primary care recruitment
across all jurisdictions up to the end of February 2016.
These preliminary data illustrate the degree to which
the recruitment strategy has been successful. An import-
ant factor has been the time it takes from diagnosis to
registration in our participating registries (it ranges from
∼1 to 4 months), given that our recruitment window is
3–6 months postdiagnosis—this window is based on
avoiding recruitment either too soon after diagnosis
(when treatment may be active), or too long—in which
case recollection of prediagnosis events might be
diminished.
In UK countries, patient questionnaire response rates
until now are typically highest for breast cancer, and
lowest in lung cancer. Recruitment in Northern Ireland
was by direct approach, and this has achieved higher
overall response rates than the other countries of the
UK—although if only rates amongt questionnaires for-
warded by PCPs in the UK are considered, the rates are
more similar. Denmark achieved higher response rates
than UK countries—the reasons for this are unclear,
and may reflect cultural and social differences which
influence willingness to respond to surveys. Responses
from primary care are consistently higher than patient
responses so far in all jurisdictions.
Assessing non-response and study validity
All jurisdictions are collecting standardised data on all
essential figures to describe internal validity and study
flow. During the study period all patients with cancer
were identified. Information on total eligible patients,
exclusions (and reasons for exclusion) and numbers
declining to participate (with their reasons) was also col-
lected. This will form the basis for an analysis of selec-
tion bias and validity of the study in terms of drawing
comparisons between countries.
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DISCUSSION
ICBPM4 is the first attempt we are aware of to describe
and compare, between countries, patient journeys to a
cancer diagnosis and treatment. While there has been
some preliminary work examining the logistics of such
comparisons,43 44 there are no previous examples of apply-
ing standardised survey methods in a broad range of inter-
national jurisdictions to systematically examine the various
components of diagnostic intervals. It is a complex exer-
cise with a broad range of methodological challenges;
nevertheless, it has the potential to highlight important
differences in diagnostic routes and these may contribute
to an understanding of variations in cancer survival.
In international studies, it is important that data col-
lection is standardised as much as possible across juris-
dictions while accommodating differences in language
and cultural understanding of health-related terms. We
have chosen to use self-completion surveys for our data
collection (except for secondary care data in Northern
Ireland and Denmark where collection from healthcare
records was considered more feasible). There are further
slight variations in the administration of the questionnaire
across jurisdictions (as described in online supplementary
file S4). Our questionnaire development drew on existing
instruments, and went through an extensive process of
cognitive testing, piloting and translation/harmonisation.
Nevertheless, the small number of patients we used in the
test–retest analysis means that our reliability estimates
have a low level of statistical precision.
We have been able to present preliminary response
rate data; our rates are similar to a Danish study which
used registry-based recruitment, and sample both
patients and PCPs (in which response rates were 79%
for PCPs and 40% for patients;42 while PCPs have much
lower response rates to general surveys, enquiry about
specific patients (as is the case in ICBPM4) appears to
lead to a significantly higher response. One of our prin-
cipal concerns is dealing with non-response and, in par-
ticular, differential response rates across jurisdictions.
Response to a survey on diagnostic journeys may be
influenced by several factors, including levels of
comorbidity, awareness of cancer symptoms, health-
seeking behaviour and participation in screening—
further, very ill patients may be under-represented due
to their circumstances—and their shorter survival.
Reasons for non-response may differ between jurisdic-
tions, and differential response rates may compound any
resulting bias. Accordingly, our analyses will include a
careful examination of sociodemographic characteristics,
and non-response bias will be explored as thoroughly as
possible with available data. All results will be carefully
scrutinised in the light of non-response issues and,
where possible, adjustments will be made—along with
clearly expressed caveats over the interpretation of our
results. There are further patient-specific factors which
ICBPM4 methods need to accommodate, including
examining the implications of previous or synchronous
cancers on self-reports of cancer journeys.
CONCLUSION
An international questionnaire-based survey (ICBPM4)
of patients, PCPs and hospital specialists has been devel-
oped and launched in 10 international jurisdictions.
In this paper, we have reported on key aspects of survey
design, questionnaire development and testing and
initial response rates.
ICBPM4 will form the basis for several analyses on
aspects of routes to cancer diagnosis and time intervals.
It will take into account a broad range of methodo-
logical limitations, and appropriate caveats will be
applied in the interpretation of results. In combination
with other ICBP modules, ICBPM4 has significant poten-
tial to help us increase the understanding of inter-
national differences in cancer survival. Combining
ICBPM4 data with data and results from other ICBP
modules will enable analyses to be undertaken on the
association between healthcare organisation, access to
investigation and public awareness of cancer symptoms
and time and routes to diagnosis. This has the potential
to inform future interventions aimed at reducing diag-
nostic intervals relating to patients, their healthcare pro-
viders and systems and thereby improving outcomes.
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